Rockefeller Capital Management L.P. Adaptimmune Therapeutics PLC Transaction History
Rockefeller Capital Management L.P.
- $47.9 Billion
- Q3 2025
A detailed history of Rockefeller Capital Management L.P. transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Rockefeller Capital Management L.P. holds 12,166 shares of ADAP stock, worth $364. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,166Holding current value
$364% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding ADAP
# of Institutions
63Shares Held
42MCall Options Held
139KPut Options Held
144K-
Long Focus Capital Management, LLC San Juan, PR18.6MShares$557,3340.1% of portfolio
-
Ubs Group Ag6.67MShares$200,0200.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny4.05MShares$121,6220.0% of portfolio
-
Morgan Stanley New York, NY3.67MShares$109,9810.0% of portfolio
-
Jane Street Group, LLC New York, NY2.81MShares$84,1600.0% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $4.9M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...